• XNK03 in Urothelial Cancer: Q&A with Dr. Anders Ullén, Karolinska University Hospital

  • New Position Paper: Characteristics & Positioning of Autologous NK Cell Therapies in Relation to Allogeneic Ditto

  • XNK Therapeutics receives GMP manufacturing license

XNK Therapeutics

Individualized NK Cell Therapies

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients.

At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed a proprietary technology platform of broad utility and benefits from its tailor-made GMP facility and co-location with the Karolinska Institute and the Karolinska University Hospital. XNK is well positioned to bring transformational autologous NK cell-based therapies and new hope to cancer patients around the world.

CEO Quarterly Statement

We can look back on yet another eventful and productive year in XNK’s history. Strengthened by the SEK 132 million funding earlier in the year from existing and new investors, led by Flerie Invest AB, we have continued to successfully develop and expand our project pipeline.